Right to Try vs Clinical Trials: What Is the Difference?

What the federal Right to Try law addresses

The federal Right to Try law, codified at 21 USC 360bbb-0a, defines a route involving certain eligible patients with life-threatening diseases or conditions and eligible investigational drugs. It establishes conditions, exceptions, and reporting rules. It does not guarantee that a manufacturer will provide a product or that a clinician will agree to participate.

This law is sometimes cited as proof that Congress can change investigational-access requirements, and that is a legitimate legislative observation. The important limit is that the existing statute does not grant every adult a general freedom to obtain any unapproved drug for self-directed study. Reading its definitions is more useful than applying its name to unrelated circumstances.

How clinical trials differ

A clinical trial is an organized research investigation involving participants and an intervention, designed to produce information under an identified protocol. Sponsors and investigators have defined roles. Depending on the study and product, the project may require an IND, consent and ethics review, safety reporting, and other controls. ClinicalTrials.gov provides information about studies and their eligibility criteria.

Participation is voluntary, but volunteering is not identical to sponsoring. A person joining an existing study may receive informed consent details and decide whether to participate. A person initiating an investigation may take on sponsor-level obligations. A legislative proposal that wants more individual research opportunities must confront that difference, not merely create a new enrollment slogan.

What expanded access does and does not do

Expanded-access programs are additional pathways through which certain patients may receive investigational medical products outside a clinical trial when regulatory conditions are met. These programs have specific criteria and procedural requirements. They do not mean experimental products are ordinary approved treatments, and they do not remove every responsibility attached to the request.

An informed discussion of research freedom should map all relevant pathways before prescribing a single solution. Some people need better navigation of existing programs; others are advocating broader statutory change. Both discussions matter, but combining them into one unqualified 'right' would obscure which agency, clinician, supplier, or sponsor is accountable.

What new legislation would have to add

A genuine Right to Research law could propose a different eligibility group, new procedures for community-led research, specific clinician protections, or participant-controlled data obligations. But those are proposals requiring precise definitions and congressional action. The practical legal question is what new permission, duty or remedy exists after enactment that did not exist before.

The initiative uses a million signatures as an organizing goal because a visible constituency can prompt public debate. It is not a formal federal threshold for introducing legislation. The petition supports that debate; it does not replace congressional sponsorship, regulation, or individual informed consent.

Questions people ask